New insider activity at Beyondspring ( (BYSI) ) has taken place on September 8, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Significant shareholder Decheng Capital China Life Sciences USD Fund III has sold 8,999 shares of Beyondspring stock, amounting to a total sale worth $17,202.
Recent Updates on BYSI stock
BeyondSpring Inc. has recently reported its Q2 2025 financial results, showcasing significant clinical advancements and strategic leadership changes. The company’s lead asset, Plinabulin, is in late-stage clinical development and has shown promising data in a Phase 2 study for NSCLC patients. Additionally, the FDA has cleared SEED Therapeutics’ RBM39 degrader ST-01156. Financially, BeyondSpring reported a net loss of $1.9 million, an improvement from the previous year, and increased cash reserves to $9.5 million. These developments, along with the strategic focus on Plinabulin’s potential to redefine cancer treatment by enhancing the body’s immune response, have positioned BeyondSpring for potential breakthroughs in cancer treatment, influencing analysts’ perspectives on the stock.
Spark’s Take on BYSI Stock
According to Spark, TipRanks’ AI Analyst, BYSI is a Neutral.
Beyondspring’s overall stock score reflects its significant financial challenges, with zero revenue and negative margins indicating severe financial distress. While technical analysis shows some positive short-term momentum, the stock is nearing overbought conditions. The negative P/E ratio highlights overvaluation concerns, significantly impacting the overall score.
To see Spark’s full report on BYSI stock, click here.
More about Beyondspring
YTD Price Performance: 16.98%
Average Trading Volume: 67,316
Technical Sentiment Signal: Sell
Current Market Cap: $75.02M